Search

Displaying results 4571 - 4580 of 8010 in total
  1. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

  2. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. … The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. … As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens

  4. Drug

    Albumin iodinated I-131 serum

    go.drugbank.com/drugs/DB09430
    Approved

    Iodinated I-131 serum albumin is a radiopharmaceutical agent used for several diagnostic purposes, including the determination of body fluid volumes and the imaging of certain tissues.[L12783]

  5. Drug

    Emedastine

    go.drugbank.com/drugs/DB01084
    Approved

    Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.

  6. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  7. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

    Categories: Heterocyclic Compounds with 4 or More Rings
  8. Drug

    Vapreotide

    go.drugbank.com/drugs/DB04894
    Investigational

    It was being studied for the treatment of cancer.

  9. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

  10. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].